Lynn Sage Breast Cancer Symposium

Arti Hurria, MD, director, Cancer and Aging Research Program, City of Hope, discusses challenges facing geriatric patients with breast cancer.

HER2-positive breast cancer has gone from "worst to first" because of the success of the monoclonal antibody drug trastuzumab in combination with chemotherapy. 

The randomized phase IIb METRIC trial could possibly pave the way for the first FDA approval for a targeted therapy for patients with triple-negative breast cancer.&nbsp;<br /> &nbsp;

Younger women with breast cancer, which make up of around 20% of patients, present with unique disease characteristics that warrant careful consideration of potentials treatments, particularly given the potential for long-term side effects.

Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses adjuvant therapy for elderly patients with HER2-positive or triple negative breast cancer (TNBC).

Breast cancer in younger women needs a different adjuvant treatment strategy from that used in post-menopausal women, but it may not have to include suppressing ovarian function.

As the breast cancer genome continues to be unraveled, a host of new targetable alterations outside of HER2 and the estrogen receptor are beginning to emerge, providing the exciting potential for development of new therapies.

Figuring out how a certain genetic result found through multigene testing might change not only the type of intervention but its timing is the chief challenge, according to Mark Robson, MD, in a presentation at the 2017 Lynn Sage Breast Cancer Symposium.

Judith Paice, PhD, RN, Robert H. Lurie Comprehensive Cancer Center, discusses the current pain management for patients with breast cancer.

Andrew Seidman, MD, discusses the Watson for Oncology application and the potential for Watson to be a valuable partner for oncologists during the&nbsp;19^th Annual Lynn Sage Breast Cancer Symposium.

Breast cancer is the most common cancer among women around the world, and those in low- and middle-income countries experience the most deaths from the disease, representing a major need for improvement with significant challenges.&nbsp;

Benjamin O. Anderson, MD, Seattle Cancer Care Alliance, discusses the current global unmet need for the treatment of patients with breast cancer.

Judith A. Paice, PhD, RN, discusses the best way to approach pain management in breast cancer.

Hope Rugo, MD, clinical professor, department of medicine, and director of Breast Oncology Clinical Trials Program, at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the role of immunotherapy in breast cancer.

Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.

PARP inhibitors&nbsp;are anything but dead as breast cancer treatment, argued Patricia LoRusso, DO.&nbsp;

Endocrine therapy has come a long way as a treatment for breast cancer since tamoxifen ruled the adjuvant therapy landscape in 1989, but much remains unknown about newer therapies and combating endocrine resistant mutations<br /> &nbsp;

Hope S. Rugo, MD, discusses&nbsp;immunotherapies, androgen receptor (AR)-targeted agents, and targeted therapies all on the horizon in TNBC.

Existing data for androgen receptor (AR) antagonists are encouraging and anticipated future results could soon show a benefit for these agents in large populations of patients with breast cancer.

Radiologists have been challenged by the ever-changing recommendations of when breast cancer screening should begin and the frequency of screening, says Sarah M. Friedewald, MD.&nbsp;The controversy surrounding screening recommendations can be a distraction to the implementation of new technologies, such as tomosynthesis.

Kimberly J. Van Zee, MS, MD, FACS, presented her findings on the benefits of nomogram during a panel on &ldquo;Breast Pathology for the Non-Pathologist&rdquo; at the 18^th annual Lynn Sage Breast Cancer Symposium in Chicago.<br /> &nbsp;

The selection process for determining which procedure to utilize for an image-directed core breast biopsy often remains a mystery to those outside of the pathology and radiology world.

William J. Gradishar, MD, discusses combining and sequencing novel targeted therapies.

In an era of simultaneous increased evaluative testing in the United States and a rise in early-stage breast cancer diagnosis, it&rsquo;s important that those facing treatment decisions for curable cancer understand the advances and advantages in precision medicine, explained Steven J. Katz, MD, MPH.

Steven Katz, MD, professor, internal medicine, at the University of Michigan Medical School, discusses the major advances in precision medicine in the field of breast cancer.